Table 1.
Characteristics of study population
| Characteristics | Patients (n = 3,044) |
|---|---|
| Age (mean, SD) |
56.8 (9.9) |
| Female (n, %) |
2444 (80.3%) |
| Race | |
| White |
2875 (94.4%) |
| Non-White |
127 (4.2%) |
| Unknown |
42 (1.4%) |
| Duration (avg. years, SD) |
17.9 (8.9) |
| DMD in previous 6 months (n, %) |
1869 (61.4)* |
| Currently working/attending school (n, %) |
1121 (36.8) |
| PDDS Score (Median, IQR) |
3 (1, 5) |
| 0 |
526 (17.3%) |
| 1 |
428 (14.1%) |
| 2 |
241 (7.9%) |
| 3 |
429 (14.0%) |
| 4 |
507 (16.7%) |
| 5 |
427 (14.0%) |
| 6 |
399 (13.1%) |
| 7 |
83 (2.7%) |
| 8 |
4 (0.13%) |
| MSWS-12 Score (Mean, SD) |
50.2 (33.7) |
| Median (Range) |
52 (0–100) |
| Tertile 1 |
1138 (37.4%) |
| Tertile 2 |
763 (25.1%) |
| Tertile 3 |
1143 (37.5%) |
| EQ-5D (Mean, SD) |
0.74 (0.18) |
| Median (Range) |
0.78 (-0.04-1.0) |
| Floor (n, %) |
0 (0%) |
| Ceiling (n, %) | 404 (13.3%) |
n = number of patients; PDDS = Patient Determined Disease Steps; MSWS-12 = 12-point Multiple Sclerosis Walking Scale; EQ-5D = EuroQol-5 Dimension Health Status Index; SD = Standard Deviation; avg = average; IQR = interquartile range; DMD = Disease-Modifying Drug; *Patients may have received ≥1 DMD in previous 6 months.